![]()
16
| 3 | 2009
Klinisk Biokemi i Norden
20. Mahley RW, Rall SC. Type III Hyperlipo
proteinemia (Dysbetalipoproteinemia):
The Role of Apolipoprotein E in Normal
and Abnormal Lipoprotein Metabolism.
In: Scriver CR, Beaudet AL, Sly WS, Valle D,
editors. The Metabolic & Molecular Bases
of Inherited Disease. 8th ed. McGraw-Hill,
2001: 2835-2862.
21. Sarti C, Gallagher J. The metabolic syn-
drome: prevalence, CHD risk, and treatment.
J Diabetes Complications 2006; 20:121-132.
22. Shaikh M, Wootton R, Nordestgaard BG,
Baskerville P, Lumley JS, La Ville AE et al.
Quantitative studies of transfer in vivo of
low density, Sf 12-60, and Sf 60-400 lipo-
proteins between plasma and arterial inti-
ma in humans. Arterioscler Thromb 1991;
11:569-577.
23. Nordestgaard BG, Tybjærg-Hansen A, Lewis
B. Influx in vivo of low density, intermediate
density, and very low density lipoproteins
into aortic intimas of genetically hyperli-
pidemic rabbits: Roles of plasma concentra-
tion, extent of aortic lesion, and lipoprotein
particle size as determinants. Arterioscler
Thromb 1992;12:6-18.
24. Nordestgaard BG. The vascular endothelial
barrier--selective retention of lipoproteins.
Curr Opin Lipidol. 1996;7:269-273.
25. Nordestgaard BG, Wootton R, Lewis B.
Selective retention of VLDL, IDL, and LDL
in the arterial intima of genetically hyper-
lipidemic rabbits in vivo. Molecular size as
a determinant of fractional loss from the
intima-inner media. Arterioscler Thromb
Vasc Biol 1995; 15:534-542.
26. Rutledge JC, Mullick AE, Gardner G,
Goldberg IJ. Direct visualization of lipid
deposition and reverse lipid transport in a
perfused artery : roles of VLDL and HDL.
Circ Res 2000; 86:768-773.
27. Gordon T, Kannel WB, Castelli WP, Dawber
TR. Lipoproteins, cardiovascular disease,
and death. The Framingham Study. Arch
Intern Med. 1981;141:1128-1131.
28. Haheim LL, Holme I, Hjermann I, Leren P.
Risk factors of stroke incidence and mortal-
ity. A 12-year follow-up of the Oslo Study.
Stroke. 1993;24:1484-1489.
29. Lindenstrom E, Boysen G, Nyboe J. Influence
of total cholesterol, high density lipoprotein
cholesterol, and triglycerides on risk of cer-
ebrovascular disease: the Copenhagen City
Heart Study. BMJ. 1994;309:11-15.
30. Simons LA, McCallum J, Friedlander
Y, Simons J. Risk factors for ischemic
stroke: Dubbo Study of the elderly. Stroke.
1998;29:1341-1346.
31. Bowman TS, Sesso HD, Ma J et al. Chole
sterol and the risk of ischemic stroke. Stroke.
2003;34:2930-2934.
32. Shahar E, Chambless LE, Rosamond WD
et al. Plasma lipid profile and incident
ischemic stroke: the Atherosclerosis Risk
in Communities (ARIC) study. Stroke.
2003;34:623-631.
33. Patel A, Barzi F, Jamrozik K et al. Serum
triglycerides as a risk factor for cardiovas-
cular diseases in the Asia-Pacific region.
Circulation. 2004;110:2678-2686.
34. Goldstein LB, Adams R, Alberts MJ et al.
Primary prevention of ischemic stroke:
a guideline from the American Heart
Association/American
Stroke
Asso
ciation Stroke Council: cosponsored by
the Atherosclerotic Peripheral Vascular
Disease Interdisciplinary Working Group;
Cardiovascular Nursing Council; Clinical
Cardiology Council; Nutrition, Physical
Activity, and Metabolism Council; and
the Quality of Care and Outcomes
Research Interdisciplinary Working Group
Circulation. 2006;113:e873-e923.
35. Zilversmit DB. Atherogenic nature of triglyc-
erides, postprandial lipidemia, and triglyc-
eride-rich remnant lipoproteins. Clin Chem
1995;41:153-8.
36. Kolovou GD, Anagnostopoulou KK,
Daskalopoulou SS, Mikhailidis DP, Cokkinos
DV. Clinical relevance of postprandial lipae-
mia. Curr Med Chem 2005;12:1931-45.
37. Proctor SD, Vine DF, Mamo JC. Arterial
retention of apolipoprotein B(48)- and
(Fortsat fra side 15)
(Fortsætter side 18)
